Abstract
The synthesis of 2-arylidene 6-(2-aryl-2-oxoethoxy)benzofuran-3-one derivatives was reported and selected compounds were determined for their anticancer activity evaluation in National Cancer Institute NCI, USA according to the drug screening protocol of the institute against approximately 60 tumor cell lines derived from nine cancer diseases. Compound 3r, namely 2-(4- chlorobenzylidene)-6-[2-(4-methoxyphenyl)-2-oxoethoxy]benzofuran-3-one exhibited the highest antitumor activity against non-small lung cancer cell lines.
Keywords: Antitumor activity, aurone, benzofuranone, chalcone, cytotoxic activity.
Letters in Drug Design & Discovery
Title:Synthesis and Antiproliferative Activity of 2-arylidene 6-(2-aryl-2-oxoethoxy)Benzofuran-3-one Derivatives
Volume: 13 Issue: 6
Author(s): Seref Demirayak, Leyla Yurttas, Ahmet Cagri Karaburun, Nalan Gundogdu-Karaburun and Ismail Kayagil
Affiliation:
Keywords: Antitumor activity, aurone, benzofuranone, chalcone, cytotoxic activity.
Abstract: The synthesis of 2-arylidene 6-(2-aryl-2-oxoethoxy)benzofuran-3-one derivatives was reported and selected compounds were determined for their anticancer activity evaluation in National Cancer Institute NCI, USA according to the drug screening protocol of the institute against approximately 60 tumor cell lines derived from nine cancer diseases. Compound 3r, namely 2-(4- chlorobenzylidene)-6-[2-(4-methoxyphenyl)-2-oxoethoxy]benzofuran-3-one exhibited the highest antitumor activity against non-small lung cancer cell lines.
Export Options
About this article
Cite this article as:
Demirayak Seref, Yurttas Leyla, Cagri Karaburun Ahmet, Gundogdu-Karaburun Nalan and Kayagil Ismail, Synthesis and Antiproliferative Activity of 2-arylidene 6-(2-aryl-2-oxoethoxy)Benzofuran-3-one Derivatives, Letters in Drug Design & Discovery 2016; 13 (6) . https://dx.doi.org/10.2174/1570180813999160429113316
DOI https://dx.doi.org/10.2174/1570180813999160429113316 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent
Current Cancer Drug Targets Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Application of Phage Display Technology to Cancer Research
Current Pharmaceutical Biotechnology Discovery of P3971 an Orally Efficacious Novel Anticancer Agent Targeting HIF-1α and STAT3 Pathways
Anti-Cancer Agents in Medicinal Chemistry High Performance Liquid Chromatographic Approaches to Mass Spectrometry Based Metabolomics
Current Metabolomics Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer
Current Pharmaceutical Design Biomedical Nano Tools: A Potential New Paradigm for Immunoassays and Immune Detection
Current Nanomedicine Synthesis and Cytotoxic Activity of 4-Aryl-4H-chromeno[4,3-d] [1,2,3] selenadiazoles
Letters in Drug Design & Discovery Recent Progress in the Synthesis of Naturally Occurring Triterpenoid Saponins
Mini-Reviews in Organic Chemistry Cytochrome P450 Structure, Function and Clinical Significance: A Review
Current Drug Targets Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Copper Compounds in Cancer Chemotherapy
Current Medicinal Chemistry Tumor Stroma Manipulation By MSC
Current Drug Targets Oncotargets in Different Renal Cancer Subtypes
Current Drug Targets Animal Models for Growth Hormone Gene Therapy
Current Gene Therapy Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Current Cancer Drug Targets Pathogenic Genes Selection Model of Genetic Disease based on Network Motifs Slicing Feedback
Current Proteomics Methionine-Independent Translation Initiation from Naturally Occurring Non-AUG Codons
Current Chemical Biology Chemodiversity in Freshwater and Terrestrial Cyanobacteria – A Source for Drug Discovery
Current Drug Targets Butyrate and Colorectal Cancer: The Role of Butyrate Transport
Current Drug Metabolism